|
|
|
| Effect of continuous infusion meropenem in the treatment of severe melioidosis pneumonia |
| XIE Tian1 WANG Min2 WU Haihong1 |
1.Pulmonary and Critical Care Medicine, Hainan Genaral Hospital, Hainan Province, Haikou 570311, China;
2.Department of Pharmacy, Hainan Genaral Hospital, Hainan Province, Haikou 570311, China |
|
|
|
Abstract Objective To observe the effect of continuous infusion meropenem in the treatment of severe melioidosis pneumonia. Methods A total of 39 cases of severe melioidosis pneumonia admitted to Hainan Genaral Hospital from January 2017 to March 2019 were selected. The patients were randomly divided into the study group (19 cases) and control group (20 cases) according to the method of random number table. The study group was given Meropenem treatment by continuous infusion, the control group was given Meropenem treatment by intermittent infusion. The total number of white blood cells, C-reactive protein (CRP), calcitonin (PCT) and acute physiology and chronic health evaluation system Ⅱ(APACHE Ⅱ) score, mechanical ventilation time, clinical curative effect, etiology clearance, 28-day-mortality and hospitalization cost of two groups were observed. Results The duration of mechanical ventilation and total hospitalization expenses in the study group were lower than those in the control group, with statistically significant differences (P ＜ 0.05). The PCT, CRP, total number of white blood cells, APACHE Ⅱ of two groups after treatment were lower than those before treatment, the differences were statistically significant (P ＜ 0.05). And the PCT, CRP, total number of white blood cells, APACHE Ⅱ were lower than the control group, the differences were statistically significant (P ＜ 0.05). The total clinical effective rate of the study group was higher than that of the control group, and the difference was statistically significant (P ＜ 0.05). There was no statistically significant difference between the two groups in etiological clearance rate, total length of stay and 28-day-mortality (P ＞ 0.05). Conclusion Continuous infusion Meropenem may provide better clinical efficacy and less economic cost than intermittent infusion on the premise of fixed dose．
|
|
|
|
|
|
[1] Wiersinga WJ，Currie BJ，Peacock SJ. Melioidosis [J]. N Engl J Med，2012，36（11）：1035-1044.
[2] 钟佳芳，陈如寿.三亚地区类鼻疽伯克霍德菌血流感染40例临床分析[J].中国热带医学，2014，14（9）：1147-1149.
[3] Currie BJ，Ward L，Cheng AC，et al. The Epidemiology and Clinical Spectrum of Melioidosis：540 Cases from the 20 Year Darwin Prospective Study [J]. PLoS Neglected Tropical Diseases，2010，4（11）：e900.
[4] Mandell LA，Wunderink RG，Anzueto A，et al. Infectious Disease Society of America/American Thoracic Society Consensus Guidelines on the Management of Commu nity-Acquired Pneumonia in Adults [J]. Clin Infect Dis，2007， 44：S27-S72.
[5] Rhodes A，Evans LE，Alhazzani W，et al. Surviving Sepsis Campaign：International Guidelines for Management of Sepsis and Septic Shock：2016 [J]. Intensive Care Med，2017，43（3）：304-377.
[6] 《抗菌药物临床试验技术指导原则》写作组.抗菌药物临床试验技术指导原则[J].中国临床药理学杂志，2014，30（9）：844-856.
[7] 张辉.青海省首例输入性人感染假鼻疽伯克霍尔德菌死亡病例[J].国际检验医学，2015，36（12）：1798-1799.
[8] 康纪明，林晓光，刘乐其，等.重庆市首例类鼻疽病例流行病学分析[J].现代预防医学，2014，41（17）：3088-3089.
[9] 谭云芳，黄增光，吴多荣，等.海南地区类鼻疽伯克霍尔德菌的药物敏感性分析[J].中国抗生素杂志，2017，42（5）：401-407.
[10] Chastre J，Luyt CE. Continuous β-Lactam Infusion to Optimize Antibiotic Use for Severe Sepsis. A Knife Cutting Water? [J]. Am J Respir Crit Care Med，2015，192（11）：1266-1268.
[11] Macvane SH，Kuti JL，Nicolau DP. Prolonging β-lactam infusion：A review of the rationale and evidence，and guidance for implementation [J]. Int J Antimicrob Agents，2014，43（2）：105-113.
[12] 张勇，丁荣，张景.美罗培南延长输注时间治疗老年人医院获得性肺炎的临床研究[J].中国感染与化疗杂志，2017，17（6）：623-628.
[13] Mattioli F，Fucile C，Del Bono V，et al. Population pharmacokinetics and probability of target attainment of meropenem in critically ill patients [J]. Eur J Clin Pharmacol，2016，72（7）：839-848.
[14] 蔺伟.美罗培南不同输注方案治疗呼吸机相关性肺炎临床效果对比观察与分析[J].中国实用医药，2016，11（28）：156-157.
[15] Zhao HY，Gu J，Lyu J，et al. Pharmacokinetic and Pharmacodynamic Efficacies of Continuous versus Intermittent Administration of Meropenem in Patients with Severe Sepsis and Septic Shock：A Prospective Randomized Pilot Study [J]. Chin Med J，2017，130（10）：1139-1145.
[16] Sj?觟vall F，Alobaid AS，Wallis SC，et al. Maximally effective dosing regimens of meropenem in patients with septic shock [J]. J Antimicrob Chemother，2018，73（1）：191-198.
[17] Yu Z，Pang X，Wu X，et al. Clinical outcomes of prolonged infusion（extended infusion or continuous infusion）versus intermittent bolus of meropenem in severe infection：A meta-analysis [J]. PLoS One，2018，13（7）：e0201667.
[18] 肖宇博，李荣凌，吴丽丽.美罗培南改良输注方式对比传统输注方式治疗严重感染疗效和安全性的Meta分析[J].中国药房，2015，26（24）：3378-3381.
[19] Dhaese SAM，Magalie DK，Maxime C，et al. Emergence of antimicrobial resistance to piperacillin/tazobactam or meropenem in the ICU：Intermittent versus continuous infusion. A retrospective cohort study [J]. J Crit Care，2018， 47：164-168.
[20] 姚莉，马红霞，范芳芳，等.美罗培南/亚胺培南延长或持续静脉输注与间隔给药比较治疗严重感染的Meta分析[J].中国循证医学杂志，2016，16（1）：73-78.
[21] Clark B，Merritt A，Inglis T，et al. Clinical features and outcome of patients with cutaneous melioidosis during a nosocomial outbreak in a temperate region of Australia [J]. Intern Med J，2018，48（4）：461-465.
[22] 谢甜，王敏，黄奕江.亚胺培南治疗类鼻疽肺炎并心包炎1例[J].临床肺科杂志，2018，23（2）：375-377. |
|
|
|
